Latest fiscal year 2024 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2024, DNA X, Inc. reported revenue of $58M, down 37.7% year over year. Operating margin was -5.3% and net margin -57.7%, on a free-cash-flow margin of -14.9% with capital expenditure at 0.4% of revenue. Every figure is computed directly from SONM's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2024 | $58M | -5.3% | -57.7% |
| FY2023 | $94M | 0.5% | -0.1% |
| FY2022 | $70M | -20.5% | -20.2% |
| FY2021 | $55M | -69.6% | -70.8% |
| FY2020 | $64M | -45.7% | -46.8% |
How does SONM compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.